Journals / Okmeydanı Tıp Dergisi / 2015 / Cilt: 31 - Sayı: 1

Local-Axillary Recurrence Rate and Affecting Factors in Patients Undergoing Breast-Conserving Surgery and Sentinel Lymph Node Biopsy

Meme Koruyucu Cerrahi ve Sentinel Lenf Nodu Biyopsisi Uygulanan Hastalarda Lokal-Aksiller Rekürrens Oranı ve Etkileyen Faktörler

Pages
27–33
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Size of tumor, existence of LVI, stage of disease and size of SLN were the factors affecting SLN positivity.Conclusion: SLNB is as reliable as ALND when locoregional relapse and distant metastasis is concerned

📌 3 Key Takeaways

🎯
Objective & Hypothesis:SLNB procedure is developed as an alternative to ALND in surgical therapy of breast cancer and is a safe staging method with low morbidity.
📊
Key Findings & Data:Our objective in the present study is to determine relapse rates in long-term follow up and the affecting factors in patients who underwent breast-conserving surgery (BCS) + SLNB.Material and Methods: In this study 171 patients treated with BCS and SLNB between 2006 and 2011, for early stage breast cancer were included.
💡
Conclusion & Impact:Size of tumor, existence of LVI, stage of disease and size of SLN were the factors affecting SLN positivity.Conclusion: SLNB is as reliable as ALND when locoregional relapse and distant metastasis is concerned
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Abstract

SLNB procedure is developed as an alternative to ALND in surgical therapy of breast cancer and is a safe staging method with low morbidity. Our objective in the present study is to determine relapse rates in long-term follow up and the affecting factors in patients who underwent breast-conserving surgery (BCS) + SLNB.Material and Methods: In this study 171 patients treated with BCS and SLNB between 2006 and 2011, for early stage breast cancer were included. In 62 of 171 patients, SLN was positive and Level 1-2 axillary dissection was applied to them. Two group of patients who had SLNB (-) and (+) have been followed up clinically and radiologically for averagely 36 months. Locoregional recurrence and metastasis rates were compared for both groups. In the lights of literature, age of patients, menopausal situation, localization of tumor, histology of tumor, size of SLN, estrogen-progesterone receptor and C erb-B2 positivity, grade of tumor, existence of extensive intraductal component, size of tumor and lymphovascular invasion were examined as possible factors that may affect rates of axillary lymph node positivity and local-axillary relapse.Results: 171 patients were followed up 36 months. In the SLNB (-) group only one patient had axillary relapse 25 months after primary surgery. Relapse rate was 0.92 %. None of SLNB (-) patients had local relapse. In the SLNB (+) group, patients underwent ALND and no one had axillary relapse, 4 had local relapse (5.84 %). 18 patients had distant metastasis. SLNB (-) patients were significantly less likely to develop local relapse. There was no significant difference in axillary relapse and distant metastasis for both groups. Size of tumor, existence of LVI, stage of disease and size of SLN were the factors affecting SLN positivity.Conclusion: SLNB is as reliable as ALND when locoregional relapse and distant metastasis is concerned

Özet

Meme kanserinin cerrahi tedavisinde sentinel lenf nodu biyopsisi (SLNB) prosedürü, aksiller lenf nodu diseksiyonuna (ALND) alternatif olarak geliştirilmiş ve düşük morbidite ile güvenli bir evreleme yöntemidir. Bu çalışmadaki amacımız Meme Koruyucu Cerrahi (MKC) + SLNB uygulanan hastalarda uzun dönemli takiplerde nüks oranlarını ve bunu etkileyen faktörleri saptamaktır.Gereç ve Yöntemler: Çalışmamıza 2006 ile 2011 tarihleri arasında erken evre meme kanseri nedeniyle MKC ve SLNB uygulanan 171 hasta dâhil edildi. Hastaların 62'sinde sentinel lenf nodu (SLN) pozitif gelmesi üzerine level 1-2 aksiller diseksiyon uygulandı. SLNB (-) ve (+) gelen iki hasta grubu ortalama 36 ay klinik ve radyolojik olarak takip edildi. Her iki gruptaki loko-rejyonel nüks ve metastaz oranları karşılaştırıldı. Literatür desteği ile aksiller lenf nodu pozitifliğini ve loko-rejyonel nüksü etkileyebilecek faktörler olarak; hastaların yaşı, menopozal durumu, tümör lokalizasyonu, tümör histolojisi, SLN boyutu, östrojen-progesteron reseptörü, c-erb-B2 pozitifliği, tümör grade'i, ekstensif intraduktal komponent (EİC) varlığı, tümör boyutu ve lenfovasküler invazyon (LVİ) varlığı incelendi.Bulgular: Yüz yetmiş bir hasta ortalama 36 ay takip edildi. SLNB (-) olan grupta ameliyattan 25 ay sonra 1 hastada aksiller nüks geliştiği saptandı, nüks oranı % 0,92'dir. SLNB (-) olan grupta lokal nüks saptanmadı. SLNB (+) gelip ALND uygulanan grupta aksiller nüks saptanmazken, 4 hastada (% 5,84) lokal nüks saptandı. On sekiz hastamızda da uzak organ metastazı belirlendi. Lokal nüks SLNB (-) olan grupta anlamlı olarak daha az iken, aksiller nüks ve uzak organ metastazı açısından iki grup arasında anlamlı fark saptanmadı. Tümör boyutu (p=0.002), LVİ varlığı (p<0.001), hastalığın evresi (p<0.001) ve SLN boyutu (p=0.014) SLN pozitifliğini etkileyen faktörler olarak saptandı.Sonuç: SLNB lokorejyonal nüks ve uzak organ metastazı açısından ALND kadar güvenilir bir yöntemdir

🔖

Cite This Article

BÜYÜKAKINCAK, S., YÜRÜKER, S. S., KOCA, B., KESİCİOĞLU, T., ÇINAR, H., EKEN, H., KARABICAK, İ., ÖZEN, N. (2015). Local-Axillary Recurrence Rate and Affecting Factors in Patients Undergoing Breast-Conserving Surgery and Sentinel Lymph Node Biopsy. Okmeydanı Tıp Dergisi, Cilt: 31 - Sayı: 1, 27–33. https://ajindex.com/articles/291815

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Brenin, D.R., Morrow M, Moughan J, et al. Manege- ment of axillary lymph node ın breast cancer: A natio- nal patterns of care study of 17,151 Patients. Ann Surg 1999;230:686-691. http://dx.doi.org/10.1097/00000658-199911000-00011
  2. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-187. http://dx.doi.org/10.1002/1097-0142(19890101) 63:1_____181::AID-CNCR2820630129>3.0.CO;2-H Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the progno- sis of patients with primary breast cancer. Cancer 1983;52:1551-1557. http://dx.doi.org/10.1002/1097-0142(19831101) 52:9_____1551::AID-CNCR2820520902>3.0.CO;2-3
  3. Silverstein MJ, Gierson ED, Waisman JR, et al. Predic- ting axillary node positivity in patients with invasive car- cinoma of the breast by using a combination of category and palpability. J Am Coll Surg 1995;180:700-704.
  4. Sakorafas GH, Tsiotou AG, Balsiger BM. Axillary lymph node dissection in breast cancer. Current sta- tus and controversies, alternative strategies and future perspectives. Acta Oncol 2000;39:455-466. http://dx.doi.org/10.1080/028418600750013366
  5. Gambazzi F, Zuber M, Oertli D, et al. Small breast carcino- mas: Less axillary surgery? Swiss Surg 2000;6:116-120. http://dx.doi.org/10.1024/1023-9332.6.3.116
  6. Christine D, Denis N, David R, et al. Axillary recur- rence after sentinel lymph node biopsy for breast ancer. The American Surgeon 2010;76:10. Lin PP, Allison DC, Wainstock J, et al. Impact of axil- lary lymph node dissection on the therapy of breast can- cer patients. J Clin Oncol 1993;11:1536-1544.
  7. Ivens D, Hoe AL, Podd TJ, et al. Assessment of mor- bidity from complete axillary dissection. Br J Cancer 1992;66:136-138. http://dx.doi.org/10.1038/bjc.1992.230
  8. Arthur Z, Krasnow H, Robert S. Lymphocintigraphy Revisted. Nucl Med Ann 1999: 17-96.
  9. Burak WE, Hollenbeck ST, Zervos EE, et al. Sentinel lymph node biopsy results in less postoperative morbi- dity compared with axillary lymph node dissection for breast cancer. Am J Surg 2002;183:23-27. http://dx.doi.org/10.1016/S0002-9610(01)00848-0
  10. Lyman GH, Giuliano AE, Somerfield MR, et al. Ame- rican Society of Clinical Oncology Guideline Recom- mendations for sentinel lymph node biopsy in early- stage breast cancer. J Clin Oncol 2005;23:7703-7720. http://dx.doi.org/10.1200/JCO.2005.08.001
  11. Schwartz GF, Giuliano AE, Veronesi U. Consensus Conference Committee. Proceedings of the consensus co